ETON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.58 USD | -0.56% |
|
-1.10% | -18.26% |
| May. 09 | Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Eton Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 128.2 | 196.9 | 105.6 | 71.34 | 112.4 | 91.97 | - |
| Enterprise Value (EV) 1 | 128.2 | 196.9 | 105.6 | 71.34 | 112.4 | 91.97 | 91.97 |
| P/E ratio | -6.99 x | -6.11 x | -53.6 x | -7.83 x | -110 x | -59.7 x | 13.3 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 134 x | 5,048 x | 4.84 x | 3.36 x | 3.55 x | 2.55 x | 1.94 x |
| EV / Revenue | 134 x | 5,048 x | 4.84 x | 3.36 x | 3.55 x | 2.55 x | 1.94 x |
| EV / EBITDA | -7.06 x | -7.44 x | -102 x | - | - | -920 x | 10.7 x |
| EV / FCF | -6.7 x | -8.79 x | -22.3 x | - | - | 70.7 x | 7.86 x |
| FCF Yield | -14.9% | -11.4% | -4.48% | - | - | 1.41% | 12.7% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17,807 | 24,214 | 24,606 | 25,297 | 25,658 | 25,691 | - |
| Reference price 2 | 7.200 | 8.130 | 4.290 | 2.820 | 4.380 | 3.580 | 3.580 |
| Announcement Date | 3/5/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.959 | 0.039 | 21.83 | 21.25 | 31.64 | 36.1 | 47.4 |
| EBITDA 1 | -18.15 | -26.46 | -1.033 | - | - | -0.1 | 8.6 |
| EBIT 1 | -18.6 | -27.11 | -1.495 | -8.26 | -1.192 | -1.3 | 7.6 |
| Operating Margin | -1,939.62% | -69,515.38% | -6.85% | -38.87% | -3.77% | -3.6% | 16.03% |
| Earnings before Tax (EBT) 1 | -18.32 | -27.97 | -1.955 | -9.021 | -0.689 | -1.7 | 7.1 |
| Net income 1 | -18.32 | -27.97 | -1.955 | -9.021 | -0.936 | -1.7 | 7.1 |
| Net margin | -1,910.32% | -71,717.95% | -8.95% | -42.45% | -2.96% | -4.71% | 14.98% |
| EPS 2 | -1.030 | -1.330 | -0.0800 | -0.3600 | -0.0400 | -0.0600 | 0.2700 |
| Free Cash Flow 1 | -19.12 | -22.4 | -4.73 | - | - | 1.3 | 11.7 |
| FCF margin | -1,993.95% | -57,425.64% | -21.67% | - | - | 3.6% | 24.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 136.05% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 164.79% |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.093 | 2.176 | 7.358 | 3.219 | 8.498 | 5.304 | 12 | 7.028 | 7.313 | 7.966 | 8.8 | 9.4 | 10 | 9.3 | 10.5 |
| EBITDA 1 | 1.451 | - | - | - | - | - | - | - | - | -0.548 | - | 0.876 | 0.971 | -0.061 | 1.093 |
| EBIT 1 | 1.314 | -5.087 | -1.34 | -2.895 | 1.062 | -2.534 | 3.883 | -0.548 | -1.993 | -0.8 | -1.7 | 0.6 | 0.7 | -0.3 | 0.8 |
| Operating Margin | 21.57% | -233.78% | -18.21% | -89.93% | 12.5% | -47.78% | 32.37% | -7.8% | -27.25% | -10.04% | -19.32% | 6.38% | 7% | -3.23% | 7.62% |
| Earnings before Tax (EBT) 1 | 1.039 | -5.33 | -1.558 | -3.045 | 0.912 | -2.66 | 4.559 | -0.579 | -2.009 | -0.811 | -1.8 | 0.4 | 0.5 | -0.5 | 0.7 |
| Net income 1 | 1.039 | -5.33 | -1.558 | -3.045 | 0.912 | -2.66 | 4.559 | -0.579 | -2.256 | -0.811 | -1.8 | 0.4 | 0.5 | -0.5 | 0.7 |
| Net margin | 17.05% | -244.94% | -21.17% | -94.59% | 10.73% | -50.15% | 38% | -8.24% | -30.85% | -10.18% | -20.45% | 4.26% | 5% | -5.38% | 6.67% |
| EPS 2 | 0.0400 | -0.2100 | -0.0600 | -0.1200 | 0.0400 | -0.1000 | 0.1800 | -0.0200 | -0.0900 | -0.0300 | -0.0700 | 0.0200 | 0.0200 | -0.0200 | 0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/16/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/14/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -19.1 | -22.4 | -4.73 | - | - | 1.3 | 11.7 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.58
USD
Average target price
8
USD
Spread / Average Target
+123.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.26% | 91.97M | |
| +8.35% | 8.72B | |
| -16.83% | 4.79B | |
| +47.36% | 4.62B | |
| +1.74% | 3.82B | |
| +14.51% | 2.33B | |
| -26.23% | 2.2B | |
| +15.63% | 2.1B | |
| -34.87% | 2.04B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- ETON Stock
- Financials Eton Pharmaceuticals, Inc.
